Anavex Life Sciences (AVXL) Other Accumulated Expenses (2020 - 2025)

Anavex Life Sciences (AVXL) has 6 years of Other Accumulated Expenses data on file, last reported at $2.0 million in Q2 2025.

• For the quarter ending Q2 2025, Other Accumulated Expenses fell 10.23% year-over-year to $2.0 million; the trailing twelve-month figure through Jun 2025 stood at $2.0 million (down 10.23% YoY), and the FY2024 full-year result was $1.9 million, down 27.93% from the prior year.
• Other Accumulated Expenses advanced to $2.0 million in Q2 2025, from $1.6 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $2.6 million in Q3 2023 to a low of $1.5 million in Q1 2024.
• A 5-year average of $2.1 million and a median of $2.1 million in 2022 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses grew 27.26% in 2023 and dropped 27.93% in 2024, its largest moves.
• Tracing AVXL's Other Accumulated Expenses over 5 years: stood at $2.2 million in 2021, then rose by 14.07% to $2.5 million in 2022, then fell by 16.55% to $2.1 million in 2023, then grew by 20.33% to $2.5 million in 2024, then slipped by 18.69% to $2.0 million in 2025.
• Business Quant data shows AVXL's Other Accumulated Expenses at $2.0 million in Q2 2025, $1.6 million in Q1 2025, and $2.5 million in Q4 2024.